Patients with HFpEF and HFmrEF have different clinical characteristics in Turkey: A multicenter observational study

Background: To determine and compare the demographic characteristics, clinical profile and management of patients with heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) in a Turkish cohort. Methods: The APOLLON trial (A comPrehensive, ObservationaL registry of heart faiLure with mid-range and preserved ejection fractiON) is an observational and multicenter study conducted in Turkey. Consecutive patients admitted to the cardiology clinics who were at least 18 years of age and had HFmrEF or HFpEF were included (NCT03026114). Results: The study population included 1065 (mean age of 67.1 ± 10.6 years, 54% women) patients from 12 sites in Turkey. Among participants, 246 (23.1%) had HFmrEF and 819 (76.9%) had HFpEF. Compared to patients with HFpEF, those with HFmrEF were more likely to be male (57.7 vs 42.2%; p < 0.001), had higher N-terminal pro-B-type natriuretic peptide levels (853 vs 528 pg/ml, p < 0.001), were more likely to have ECG abnormalities (72.4 vs 53.5%, p < 0.001) and hospitalization history for heart failure (28 vs 18.6%; p = 0.002). HFmrEF patients were more likely to use ß-blockers (69.9 vs 55.2%, p < 0.001), aldosterone receptor antagonists (24 vs 14.7%, p = 0.001), statins (37 vs 23%, p < .001), and loop diuretics (39.8 vs 30.5%, p = 0.006) compared to patients with HFpEF. Conclusions: The results of APOLLON study support that the basic characteristics and etiology of HFmrEF are significantly different from HFpEF. This registry also showed that the patients with HFmrEF and HFpEF were younger but undertreated in Turkey compared to patients in western countries. © 2018 European Federation of Internal Medicine

Yazar Özlek B.
Özlek E.
Ağuş H.Z.
Tekinalp M.
Kahraman S.
Çil C.
Çelik O.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/6933
Tek Biçim Adres 10.1016/j.ejim.2018.11.001
Konu Başlıkları Clinic profile
Epidemiology
Heart failure with mid-range ejection fraction
Heart failure with preserved ejection fraction
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı European Journal of Internal Medicine
Dergi Cilt Bilgisi 61
Sayfalar 88 - 95
Yayın Yılı 2019
Eser Adı
[dc.title]
Patients with HFpEF and HFmrEF have different clinical characteristics in Turkey: A multicenter observational study
Yazar
[dc.contributor.author]
Özlek B.
Yazar
[dc.contributor.author]
Özlek E.
Yazar
[dc.contributor.author]
Ağuş H.Z.
Yazar
[dc.contributor.author]
Tekinalp M.
Yazar
[dc.contributor.author]
Kahraman S.
Yazar
[dc.contributor.author]
Çil C.
Yazar
[dc.contributor.author]
Çelik O.
Yayın Yılı
[dc.date.issued]
2019
Yayıncı
[dc.publisher]
Elsevier B.V.
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Background: To determine and compare the demographic characteristics, clinical profile and management of patients with heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) in a Turkish cohort. Methods: The APOLLON trial (A comPrehensive, ObservationaL registry of heart faiLure with mid-range and preserved ejection fractiON) is an observational and multicenter study conducted in Turkey. Consecutive patients admitted to the cardiology clinics who were at least 18 years of age and had HFmrEF or HFpEF were included (NCT03026114). Results: The study population included 1065 (mean age of 67.1 ± 10.6 years, 54% women) patients from 12 sites in Turkey. Among participants, 246 (23.1%) had HFmrEF and 819 (76.9%) had HFpEF. Compared to patients with HFpEF, those with HFmrEF were more likely to be male (57.7 vs 42.2%; p < 0.001), had higher N-terminal pro-B-type natriuretic peptide levels (853 vs 528 pg/ml, p < 0.001), were more likely to have ECG abnormalities (72.4 vs 53.5%, p < 0.001) and hospitalization history for heart failure (28 vs 18.6%; p = 0.002). HFmrEF patients were more likely to use ß-blockers (69.9 vs 55.2%, p < 0.001), aldosterone receptor antagonists (24 vs 14.7%, p = 0.001), statins (37 vs 23%, p < .001), and loop diuretics (39.8 vs 30.5%, p = 0.006) compared to patients with HFpEF. Conclusions: The results of APOLLON study support that the basic characteristics and etiology of HFmrEF are significantly different from HFpEF. This registry also showed that the patients with HFmrEF and HFpEF were younger but undertreated in Turkey compared to patients in western countries. © 2018 European Federation of Internal Medicine
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Clinic profile
Konu Başlıkları
[dc.subject]
Epidemiology
Konu Başlıkları
[dc.subject]
Heart failure with mid-range ejection fraction
Konu Başlıkları
[dc.subject]
Heart failure with preserved ejection fraction
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0953-6205
İlk Sayfa Sayısı
[dc.identifier.startpage]
88
Son Sayfa Sayısı
[dc.identifier.endpage]
95
Dergi Adı
[dc.relation.journal]
European Journal of Internal Medicine
Dergi Cilt Bilgisi
[dc.identifier.volume]
61
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1016/j.ejim.2018.11.001
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/6933
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
17
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
17 Nisan 2024 01:53
Google Kontrol
Tıklayınız
patients HFmrEF likely failure Turkey ejection registry compared APOLLON included preserved fraction mid-range characteristics ß-blockers history hospitalization receptor abnormalities levels aldosterone Background antagonists undertreated different showed younger western countries European Federation Internal significantly etiology statins
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms